CRISPR Gene Editing in Drug Discovery: Applications and Future

Introduction

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing has fundamentally transformed biological research and drug discovery since its introduction as a programmable genome editing tool in 2012. What began as a bacterial immune defense system has been repurposed into a precise, versatile, and scalable platform for modifying genetic material in virtually any organism. The impact of CRISPR on drug discovery is multifaceted: it accelerates target identification, enables creation of disease models, facilitates functional genomics screens, and—most remarkably—serves as a therapeutic modality in its own right.

The 2020 Nobel Prize in Chemistry awarded to Jennifer Doudna and Emmanuelle Charpentier for their discovery of the CRISPR-Cas9 system underscored the technology’s scientific significance. Today, CRISPR-based therapeutics have moved from concept to clinical reality, with the FDA approval of Casgevy (exa-cel) for sickle cell disease in late 2023 marking a historic milestone. This article explores the mechanisms, applications, challenges, and future directions of CRISPR in drug discovery. For the latest CRISPR research updates, visit the CodeDrug news section.

CRISPR Systems: Mechanisms and Variants

CRISPR-Cas9: The Workhorse

The CRISPR-Cas9 system is the most widely used genome editing tool. It consists of two key components:

• Cas9 nuclease: An enzyme that creates double-strand breaks in DNA at locations specified by a guide RNA
• Single guide RNA (sgRNA): A synthetic RNA molecule (~100 nucleotides) that contains a 20-nucleotide spacer sequence complementary to the target DNA, fused to a Cas9-binding scaffold

When the Cas9-sgRNA complex encounters a target sequence adjacent to a PAM (Protospacer Adjacent Motif, typically NGG for SpCas9), it unwinds the DNA, checks for complementarity, and if matched, cleaves both DNA strands. The resulting double-strand break is repaired by one of two cellular mechanisms:

• Non-homologous end joining (NHEJ): An error-prone process that often introduces insertions or deletions (indels), leading to gene knockout
• Homology-directed repair (HDR): A precise repair mechanism that uses a provided DNA template to make specific sequence changes, enabling knock-in or correction

Cas12 and Cas13 Variants

Beyond Cas9, other Cas enzymes have expanded the CRISPR toolkit:

System	Target	Key Features
Cas12 (Cpf1)	DNA	Creates staggered cuts; recognizes T-rich PAMs; smaller size for easier delivery
Cas13	RNA	Targets RNA instead of DNA; reversible editing; no permanent genomic changes
Cas12b	DNA	Compact size; high specificity; compatible with AAV delivery
Base editors	DNA	Converts individual bases without double-strand breaks (C→T, A→G)
Prime editors	DNA	Performs all 12 base-to-base conversions and small insertions/deletions using a pegRNA

Applications in Drug Discovery

Functional Genomics Screening

CRISPR has become the gold standard for functional genomics screening, replacing older RNA interference (RNAi) approaches in many applications. Two main screening strategies are employed:

Pooled CRISPR screens deliver genome-wide sgRNA libraries to cell populations via lentiviral transduction. Cells are then subjected to a selective pressure (e.g., drug treatment, viral infection, nutrient deprivation), and sgRNA enrichment or depletion is quantified by next-generation sequencing. This approach enables identification of:

• Genes essential for cell survival in specific cancer types (synthetic lethality)
• Mechanisms of drug resistance
• Host factors required for pathogen replication
• Regulators of specific signaling pathways

Arrayed CRISPR screens perturb one gene per well, enabling high-content phenotypic readouts such as imaging-based assays. While less scalable than pooled screens, arrayed approaches provide richer phenotypic information.

Disease Modeling

CRISPR enables rapid generation of isogenic disease models by introducing specific mutations into cell lines or animal models. This approach offers several advantages over traditional disease modeling:

• Isogenic controls: Mutations are introduced into the same genetic background, eliminating confounding genetic variation
• Patient-specific models: CRISPR can correct disease-causing mutations in patient-derived induced pluripotent stem cells (iPSCs) to create corrected control lines
• Multiplex editing: Multiple genes can be simultaneously modified to model polygenic diseases

Target Validation

CRISPR provides powerful tools for validating drug targets identified through other methods. Knockout of the target gene can confirm its role in disease-relevant phenotypes, while CRISPRa (activation) can model gain-of-function scenarios. This integration of CRISPR with drug target identification methods strengthens the evidence base for target selection.

CRISPR as a Therapeutic Modality

In Vivo Gene Editing

Direct delivery of CRISPR components to target tissues in the body represents the next frontier. Notable advances include:

• Liver-targeted editing: LNPs preferentially accumulate in the liver, making hepatic diseases ideal targets. NTLA-2001, an LNP-delivered CRISPR therapy for transthyretin amyloidosis, has shown sustained protein reduction in clinical trials.
• Eye disorders: Subretinal injection of AAV-delivered CRISPR for inherited retinal dystrophies
• In vivo base editing: PCSK9 base editing for cardiovascular disease has entered clinical development

Ex Vivo Gene Editing

Ex vivo approaches involve editing cells outside the body before reinfusion. The approved therapy Casgevy exemplifies this approach:

1. CD34+ hematopoietic stem cells are collected from the patient
2. CRISPR-Cas9 disrupts the BCL11A erythroid enhancer, reactivating fetal hemoglobin production
3. Edited cells are reinfused after myeloablation
4. Fetal hemoglobin compensates for defective adult hemoglobin in sickle cell patients

Other ex vivo applications include engineering CAR-T cells with CRISPR to improve persistence and reduce exhaustion, and editing iPSCs for regenerative medicine applications.

Off-Target Effects and Safety

Understanding Off-Target Editing

A primary concern with CRISPR therapeutics is off-target editing—unintended modifications at genomic sites with sequence similarity to the target. Off-target effects can potentially disrupt normal gene function, activate oncogenes, or cause chromosomal rearrangements.

Detection Methods

Several methods have been developed to detect and quantify off-target editing:

• GUIDE-seq: Captures double-strand breaks genome-wide using oligonucleotide integration
• CIRCLE-seq: In vitro cleavage of circularized genomic DNA followed by sequencing
• Digenome-seq: In vitro cleavage of genomic DNA followed by whole-genome sequencing
• CHANGE-seq: An improved CIRCLE-seq variant with higher sensitivity

Strategies to Improve Specificity

Researchers have developed multiple approaches to minimize off-target effects:

• Engineered Cas9 variants: High-fidelity Cas9 variants (eSpCas9, SpCas9-HF1, HiFi Cas9) with reduced off-target activity
• Truncated sgRNAs: Shorter guide RNAs (17–18 nucleotides) reduce off-target binding
• Nickases: Using a Cas9 nickase that cuts only one strand requires paired sgRNAs, effectively doubling the specificity requirement
• Ribonucleoprotein (RNP) delivery: Direct delivery of Cas9 protein-sgRNA complexes reduces exposure time compared to viral delivery, limiting off-target editing

Challenges and Future Directions

Delivery Challenges

Efficient delivery of CRISPR components to target tissues remains a significant hurdle. While LNP delivery works well for the liver, targeting other organs (brain, heart, lungs, muscles) requires novel delivery vehicles. Promising approaches include:

• Engineered AAV serotypes with tissue-specific tropism
• Ligand-conjugated LNPs for receptor-mediated targeting
• Virus-like particles (VLPs) that deliver CRISPR ribonucleoproteins
• Exosome-based delivery systems

Ethical and Regulatory Considerations

The power of CRISPR raises important ethical questions, particularly regarding germline editing (modifications that can be inherited). The scientific community has largely agreed to refrain from heritable germline editing, but somatic cell editing for therapeutic purposes continues to advance under regulatory oversight. The FDA and other agencies have established specialized review pathways for gene editing therapeutics.

Emerging Frontiers

• Epigenome editing: CRISPR-based tools that modify DNA methylation and histone marks without altering the DNA sequence
• Transcriptional regulation: CRISPRi and CRISPRa for reversible gene expression modulation
• Multiplex editing: Simultaneous editing of multiple genomic loci for complex trait engineering
• CRISPR diagnostics: SHERLOCK and DETECTR platforms for molecular diagnostics using Cas12/Cas13

Conclusion

CRISPR gene editing has established itself as an indispensable tool in drug discovery, from target identification and validation to therapeutic development. The technology’s precision, scalability, and versatility have opened therapeutic possibilities that were unimaginable a decade ago. As delivery technologies improve and safety profiles are better understood, CRISPR-based therapeutics are likely to expand beyond rare genetic diseases into more common conditions. The integration of CRISPR with other emerging technologies, including AI-driven drug discovery and mRNA delivery platforms, will further accelerate the translation of genetic insights into effective therapies. For researchers exploring CRISPR-related drug data, the CodeDrug database and research tools provide valuable resources.